Randomized Control Trial Comparing Oral Amoxicillin-clavulanate and Ofloxacin With Intravenous Ceftriaxone and Amikacin as Outpatient Therapy in Pediatric Low-risk Febrile Neutropenia
Authors:
- Chetanya SwaroopCSChetanya Swaroop
- Sandeep AgarwalaSASandeep Agarwala
- Ravindra Mohan PandeyRPRavindra Mohan Pandey
- Sameer BakhshiSBSameer Bakhshi
- 1 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 31 (9) , 635-641
Abstract
Outpatient oral therapy is infrequently used in pediatric low-risk febrile neutropenia (LRFN) as there is insufficient data regarding its equivalence as compared with parenteral therapy. This is a single institutional, randomized control trial in pediatric LRFN aged 2 to 15 years, in which 123 episodes in 88 patients were randomized to outpatient oral ofloxacin 7.5 mg/kg 12 hourly and amoxycillin-clavulanate 12.5 mg/kg 8 hourly or outpatient intravenous (IV) ceftriaxone 75 mg/kg and amikacin 15 mg/kg once daily after blood cultures. Out of 119 evaluable episodes, one-third were leukemia patients in maintenance and rest were solid tumors. Success was achieved in 55/61 (90.16%) and 54/58 (93.1%) in oral and IV arms, respectively, (P=0.56). There were 3 hospitalizations but no mortality. Median days to resolution of fever, absolute neutrophil count >500/mm(3) and antibiotic use were 3, 5, and 6 days in both arms. There were 5 blood culture isolates (3 gram-positive and 2 gram-negative bacteria). Failure of outpatient therapy was associated with perianal infections, bacteremia, febrile neutropenia onset before day 9 of chemotherapy in solid tumors and Vincristine, actinomycin-D, and cyclophosphamide chemotherapy for rhabdomyosarcoma. All gram-positive isolates were successes, whereas both gram-negative isolates were failures. Diarrhea in IV arm and Vincristine, actinomycin-D, and cyclophosphamide chemotherapy in the oral arm predicted failure in subgroup analysis. Outpatient therapy is efficacious and safe in pediatric LRFN. There was no difference in outcome in oral versus IV outpatient therapy. Amoxycillin-clavulanate and ofloxacin may be the oral regimen of choice.Keywords
This publication has 24 references indexed in Scilit:
- Risk prediction of fever in neutropenia in children with cancer: A step towards individually tailored supportive therapy?Pediatric Blood & Cancer, 2008
- Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropeniaPediatric Blood & Cancer, 2007
- Outpatient, sequential, parenteral‐oral antibiotic therapy for lower risk febrile neutropenia in children with malignant diseaseCancer, 2003
- Evolving concepts of management of febrile neutropenia in children with cancerMedical and Pediatric Oncology, 2002
- 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with CancerClinical Infectious Diseases, 2002
- Oral Cefixime Is Similar to Continued Intravenous Antibiotics in the Empirical Treatment of Febrile Neutropenic Children with CancerClinical Infectious Diseases, 2001
- Outpatient treatment with ceftriaxone alone or incombination with teicoplanin in febrile neutropenic children and adolescentswith cancerThe Journal of Pediatrics, 1997
- A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremiaThe Journal of Pediatrics, 1996
- Early Discharge Of Pediatric Febrile Neutropenic Cancer Patients By Substitution Of Oral For Intravenous AntibioticsPediatric Hematology and Oncology, 1994
- Controversies in the Management of Febrile Neutropenic Cancer PatientsCancer Investigation, 1988